Assessment of the rate of long-term complete remission off therapy in patients with pemphigus treated with different regimens including medium- and high-dose corticosteroids

被引:53
|
作者
Almugairen, Naif [1 ]
Hospital, Valerie [3 ]
Bedane, Christophe [4 ]
Duvert-Lehembre, Sophie [1 ]
Picard, Damien [1 ]
Tronquoy, Anne-Fleur [1 ]
Houivet, Estelle [2 ]
D'incan, Michel [3 ]
Joly, Pascal [1 ]
机构
[1] Univ Rouen, Rouen Univ Hosp, Dept Dermatol, Inst Res & Innovat Biomed,INSERM,U905, F-76821 Mont St Aignan, France
[2] Univ Rouen, Rouen Univ Hosp, Dept Biostat, F-76821 Mont St Aignan, France
[3] Clermont Ferrand Univ Hosp, Dept Dermatol, Clermont Ferrand, France
[4] Limoges Univ Hosp, Dept Dermatol, Limoges, France
关键词
follow-up; pemphigus; treatment; VULGARIS; DISEASE;
D O I
10.1016/j.jaad.2013.05.016
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Few studies have evaluated pemphigus treatments according to the definitions of the consensus statement. Prognostic factors for complete remission off therapy (CRoffT) remain unknown. Objective: We sought to assess the rate of CRoffT in patients with pemphigus treated with different regimens. Methods: In all, 134 patients with pemphigus were included in a retrospective, multicenter study. Primary end point was the rate of CRoffT. Prognostic factors for CRoffT were determined using univariate and multivariate analyses. Results: Eighty patients with pemphigus vulgaris, 47 with pemphigus foliaceus, and 7 with paraneoplastic pemphigus were included. Mean age was 60 +/- 18 years. Patients were treated either with medium (<= 0.5 mg/kg/d) (n = 32) or high (>= 1 mg/kg/d) (n = 59) doses of prednisone, or without systemic corticosteroids (n = 43). Mean follow-up was 77 +/- 64 months. In all, 68 patients (50.7%) achieved CRoffT (95% confidence interval 42.3%-59.2%) after a mean treatment duration of 36 +/- 39 months, including 47 of 80 patients with pemphigus vulgaris (58.7%) and 21 of 47 with pemphigus foliaceus (44.7%). Main prognostic factors for CRoffT were initial mucosal involvement (hazard ratio 2.2; 95% confidence interval 1.05-4.58; P = .036) and younger age (<61 years) (hazard ratio 2.5; 95% confidence interval 1.18-5.12; P = .0167). The rate of long-lasting CRoffT was 44%, with a mean follow-up after treatment withdrawal of 59 +/- 50 months. Limitations: This was a retrospective study. Conclusion: The rate of CRoffT was 51%. Patients with pemphigus vulgaris were more likely to achieve CRoffT than those with pemphigus foliaceus.
引用
收藏
页码:583 / 588
页数:6
相关论文
共 50 条
  • [1] Factors associated with long-term complete remission in pemphigus patients receiving rituximab therapy
    Hsu, Hao-Chen
    Huang, Po-Wei
    Cho, Yung-Tsu
    Chu, Chia-Yu
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024,
  • [2] Necrotizing scleritis associated with rheumatoid arthritis: long-term remission with high-dose infliximab therapy
    Ashok, D
    Ayliffe, WH
    Kiely, PDW
    RHEUMATOLOGY, 2005, 44 (07) : 950 - 951
  • [3] Long-term results in multiple myeloma treated with high-dose melphalan and autologous peripheral stem cell transplantation and achieving complete remission.
    Martino, Massimo Vincenzo
    Postorino, Maurizio
    Gallo, Giuseppe Alberto
    Irrera, Giuseppe
    Piro, Eugenio
    Messina, Giuseppe
    Neri, Santo
    Al Sayyad, Said
    Fedele, Roberta
    Musolino, Caterina
    Molica, Stefano
    Brugiatelli, Maura
    Nobile, Francesco
    Morabito, Fortunato
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma
    Pott, C
    Schrader, C
    Gesk, S
    Harder, L
    Tiemann, M
    Raff, T
    Brüggemann, M
    Ritgen, M
    Gahn, B
    Unlerhalt, M
    Dreyling, M
    Hiddemann, W
    Siebert, R
    Dreger, P
    Kneba, M
    BLOOD, 2006, 107 (06) : 2271 - 2278
  • [5] Long-term outcome in pcnsl patients treated with high-dose methotrexate and deferred radiation
    Gerstner, Elizabeth R.
    Carson, Kathryn A.
    Grossman, Stuart A.
    Batchelor, Tracy T.
    NEUROLOGY, 2008, 70 (05) : 401 - 402
  • [6] Long-Term, Drug-Free Remission of Sympathetic Ophthalmia with High-Dose, Short-Term Chlorambucil Therapy
    Patel, Sarju S.
    Dodds, Emilio M.
    Echandi, Laura V.
    Couto, Cristobal A.
    Schlaen, Ariel
    Tessler, Howard H.
    Goldstein, Debra A.
    OPHTHALMOLOGY, 2014, 121 (02) : 596 - 602
  • [7] Bone remodeling and structure in postmenopausal women treated with long-term, high-dose estrogen therapy
    Vedi, S
    Purdie, DW
    Ballard, P
    Bord, S
    Cooper, AC
    Compston, JE
    OSTEOPOROSIS INTERNATIONAL, 1999, 10 (01) : 52 - 58
  • [8] Bone Remodeling and Structure in Postmenopausal Women Treated with Long-Term, High-Dose Estrogen Therapy
    S. Vedi
    D. W. Purdie
    P. Ballard
    S. Bord
    A. C. Cooper
    J. E. Compston
    Osteoporosis International, 1999, 10 : 52 - 58
  • [9] Burden of Persistent Asthma in Patients Treated With Medium- to High-Dose Inhaled Corticosteroids: Baseline Data From a Phase 2 Clinical Trial of Dupilumab
    Corren, Jonathan
    Castro, Mario
    Joish, Vijay
    Mastey, Vera
    Amand, Caroline
    Taniou, Christine
    Evans, Robert
    Tisserand, Mariana Louis
    Teper, Ariel
    Eckert, Laurent
    CHEST, 2015, 148 (04)
  • [10] Long-term Survival and Toxicity in Patients Treated With High-Dose Intensity Modulated Radiation Therapy for Localized Prostate Cancer
    Spratt, Daniel E.
    Pei, Xin
    Yamada, Josh
    Kollmeier, Marisa A.
    Cox, Brett
    Zelefsky, Michael J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 85 (03): : 686 - 692